Table 3.
Comparison of clinical and blood-based characteristics between groups with high and low pan-inflammation values.
| Variable | Low PIV (<368) | High PIV (≥368) | All | p Value |
|---|---|---|---|---|
|
Subtype Luminal A/B HER2-positive Triple-negative |
20 (55.6) 5 (41.7) 4 (40) |
16 (44.4) 7 (58.3) 6 (60) |
36 (62.1) 12 (20.7) 10 (17.2) |
0.555 |
|
Type of therapy Endocrine Chemotherapy |
13 (68.4) 16 (42.1) |
6 (31.6) 22 (57.9) |
19 (33.3) 38 (66.7) |
0.061 |
|
Line of therapy 1st–2nd line 3rd–4th line ≥5th line |
14 (53.8) 10 (52.6) 5 (38.5) |
12 (46.2) 9 (47.4) 8 (61.5) |
26 (44.8) 19 (32.8) 13 (22.4) |
0.638 |
|
Cycle of therapy 1st–2nd cycle ≥3rd cycle |
10 (41.7) 19 (55.9) |
14 (58.3) 15 (44.1) |
24 (41.4) 34 (58.6) |
0.286 |
|
Skeletal metastases No Yes |
6 (28.6) 23 (62.2) |
15 (71.4) 14 (37.8) |
21 (36.2) 37 (63.8) |
0.014 |
|
Liver metastases No Yes |
13 (52) 16 (48.5) |
12 (48) 17 (51.5) |
25 (43.1) 33 (56.9) |
0.791 |
|
CTC clusters No Yes |
26 (49.1) 3 (60) |
27 (50.9) 2 (40) |
54 (91.4) 5 (8.6) |
0.640 |
|
Megakaryocytes No Yes |
17 (63) 12 (38.7) |
10 (37) 19 (61.3) |
27 (46.6) 31 (53.4) |
0.065 |
|
CTC group 0 CTC 1–4 CTC ≥5 CTC |
5 (41.7) 10 (50) 14 (53.8) |
7 (58.3) 10 (50) 12 (46.2) |
12 (20.7) 20 (34.5) 26 (44.8) |
0.784 |
SII: Systemic immune-inflammation index (SII), PIV: Pan-inflammatory value, CTCs: Circulating tumor cells.